title: Once-daily fosinopril in the treatment of hypertension.
abstract: This multicenter, dose-ranging study evaluated the antihypertensive effectiveness of once-daily administration of fosinopril sodium in 220 patients with supine diastolic blood pressure of 95-115 mm Hg. After a 4-week placebo period, patients were randomly assigned to double-blind therapy with either placebo or 10, 40, or 80 mg fosinopril once daily for 4 weeks. If treatment goals were not met, chlorthalidone 25 mg/day was added for weeks 5 to 8. Thereafter, patients could enter the long-term, open-label phase and receive 10-80 mg/day fosinopril plus chlorthalidone, if needed. After 4 weeks of monotherapy, the average decreases in supine diastolic blood pressure were 9% (10 mg), 11.5% (40 mg), and 12.5% (80 mg) compared with 6% in the placebo group. After 8 weeks, the average decreases, with or without diuretic therapy, were 12.5-18.2%, compared with 10.8% with placebo. Blood pressure continued to be well controlled, and the patients showed no evidence of tachyphylaxis or tolerance through 12-15 months of treatment. Fosinopril was well tolerated. During the short-term phase, no patient withdrew because of adverse events possibly related to fosinopril; during the long-term phase, nine of 148 patients (6.1%) withdrew for that reason. In patients with mild-to-moderate hypertension, once-daily fosinopril (40 and 80 mg) provided significant antihypertensive effects with or without diuretic therapy. The 10 mg dose was effective in some patients and may be considered a starting dose.
authors.affiliation: University of Colorado, Denver.
authors.forename: R J
authors.initials: RJ
authors.lastname: Anderson
authors.forename: K L
authors.initials: KL
authors.lastname: Duchin
authors.forename: R D
authors.initials: RD
authors.lastname: Gore
authors.forename: T S
authors.initials: TS
authors.lastname: Herman
authors.forename: R S
authors.initials: RS
authors.lastname: Michaels
authors.forename: P S
authors.initials: PS
authors.lastname: Nichola
authors.forename: T M
authors.initials: TM
authors.lastname: Nolen
authors.forename: P
authors.initials: P
authors.lastname: Wolfson
authors.forename: D G
authors.initials: DG
authors.lastname: Wombolt
authors.forename: R
authors.initials: R
authors.lastname: Zusman
mesh_terms: D000959:Antihypertensive Agents / Q000627:therapeutic use; D001794:Blood Pressure; D002752:Chlorthalidone / Q000627:therapeutic use; D004311:Double-Blind Method; D004359:Drug Therapy, Combination; D005260:Female; D017328:Fosinopril; D006801:Humans; D006973:Hypertension / Q000188:drug therapy* / Q000503:physiopathology; D008297:Male; D011392:Proline / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D013484:Supination; D013997:Time Factors
chemical_list: D000959:Antihypertensive Agents; D011392:Proline; D002752:Chlorthalidone; D017328:Fosinopril